A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol fumarate (BGF) metered dose inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants with Chronic Obstructive Pulmonary Disease (COPD).

Trial Identifier: D5988C00001
Sponsor: AstraZeneca
Start Date: October 2023
Primary Completion Date: January 2026
Study Completion Date: January 2026
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, AB Edmonton, AB, CA, T6G 2B7
CA, ON Kingston, ON, CA, K7L 2V7
CA, QC Sainte Foy, QC, CA, G1V 4G5
CN Guangzhou, CN, 510163
CN Nanchang, CN, 330006
CN Shenyang, CN, 110001
CN Zhengzhou, CN, 450000
DE Berlin, DE, 14050
DE Berlin, DE, 12159
DE Frankfurt, DE, 60596
DE Großhansdorf, DE, 22927
DE Hannover, DE, 30449
DE Heidelberg, DE, 69115
DE Lübeck, DE, 23552
DE Mainz, DE, 55128
ES Benalmádena, ES, 29630
ES Madrid, ES, 28007
ES Santiago de Compostela, ES, 15706
ES Sevilla, ES, 41013
GB Leicester, GB, LE1 5WW
GB London, GB, SW3 6HP
GB London, GB, W1T 6AH
GB Manchester, GB, M23 9GP
KR Daegu, KR, 42415
KR Seoul, KR, 05030
KR Seoul, KR, 02447
US, CA Los Angeles, CA, US, 90095
US, CA Tarzana, CA, US, 91356
US, CA Torrance, CA, US, 90502
US, FL Brooksville, FL, US, 34613
US, SC Anderson, SC, US, 29621
US, SC Greenville, SC, US, 29615
US, SC Spartanburg, SC, US, 29303